Youth-Nominated Support Teams for High Risk of Psychosis

(YST Trial)

Overseen By Jason E Schiffman, PhD

Age: < 65

Sex: Any

Trial Phase: Academic

Sponsor: University of California, Irvine

Disqualifiers: Previous study phases, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

70 Participants Needed

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment Youth-Nominated Support Teams for CHR in high-risk youth for psychosis?

The research highlights the importance of engaging clinically high-risk youth in treatment to prevent complications, and suggests that specialized support teams and training can improve service provision for young people with early psychosis. While specific data on Youth-Nominated Support Teams is not provided, the emphasis on treatment engagement and specialized care supports the potential effectiveness of such interventions. ^{1 2 3 4 5}

How is the Youth-Nominated Support Teams treatment different from other treatments for high risk of psychosis?

The Youth-Nominated Support Teams treatment is unique because it involves support from individuals chosen by the young person at risk, focusing on personalized social support rather than traditional medical or therapeutic interventions. This approach emphasizes the role of social networks and family dynamics in managing symptoms and improving functioning, which is different from standard treatments that often focus on medication or therapy alone. ^{1 3 5 6 7}

What is the purpose of this trial?

This study aims to adapt the current Youth-Nominated Support Team (YST) manual used to treat suicide risk for people at clinical high risk for psychosis.

Eligibility Criteria

This trial is for young people aged 12-25 who have thought about or attempted suicide in the past year and are at high risk for psychosis. Participants should be receiving or have received treatment for symptoms related to psychosis risk.

Inclusion Criteria

I am between 12 and 25 years old.

I have thought about or attempted suicide recently.

A person who is receiving or has received treatment for psychosis risk symptoms

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Adaptation and Implementation

Adaptation of the YST intervention for CHR populations based on stakeholder input and implementation in a single CHR clinic

6 weeks

Pilot Randomized Clinical Trial

Conduct a pilot randomized clinical trial at four SAMHSA funded CHR sites to test the efficacy of the adapted YST intervention

3 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

3 months

Treatment Details

Interventions

• Youth-Nominated Support Teams for CHR

Trial Overview The study is testing an adapted version of the Youth-Nominated Support Team (YST) approach, which was originally designed to address suicide risk but now includes support for those at clinical high risk for psychosis.

Participant Groups

Group I: YST-CHR Group Experimental Treatment 1 Intervention

This group will recieve the new adapted YST treatment (YST-CHR). Clinicians will administer this treatment. Neither group will be blind.

Group II: Treatment as usual Active Control 1 Intervention

This group will receive their usual therapy/treatment as usual.

Who Is Running the Clinical Trial?

University of California, Irvine

Lead Sponsor

Trials

580

Recruited

4,943,000+

University of Maryland, Baltimore County

Collaborator

Trials

13

Recruited

2,400+

References

1. England pubmed.ncbi.nlm.nih.gov

Changes in early psychosis service provision: a file audit. [2017]

2. Australia pubmed.ncbi.nlm.nih.gov

The Common Elements of treatment engagement for clinically high-risk youth and youth with first-episode psychosis. [2017]

3. United States pubmed.ncbi.nlm.nih.gov

Canadian Treatment Guidelines for Individuals at Clinical High Risk of Psychosis. [2022]

4. United States pubmed.ncbi.nlm.nih.gov

Patient-Reported Outcome Measures in Clinical High Risk for Psychosis: A Systematic Review. [2023]

5. United States pubmed.ncbi.nlm.nih.gov

Negative Symptom Interventions in Youth at Risk of Psychosis: A Systematic Review and Network Meta-analysis. [2023]

6. Switzerland pubmed.ncbi.nlm.nih.gov

A network analysis of anxiety, depressive, and psychotic symptoms and functioning in children and adolescents at clinical high risk for psychosis. [2023]

7. Netherlands pubmed.ncbi.nlm.nih.gov

Family functioning moderates the impact of psychosis-risk symptoms on social and role functioning. [2020]